Design Therapeautics, Inc. Share Price Today: Live Updates & Key Insights

Design Therapeautics, Inc. share price today is $10.31, up 0.49%. The stock opened at $10.3 against the previous close of $10.26, with an intraday high of $10.45 and low of $10.19.

Design Therapeautics, Inc. Share Price Chart

Design Therapeautics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Design Therapeautics, Inc. Share Price Performance

$10.31 0.0049(0.49%) DSGN at 23 Mar 2026 12:46 PM Biotechnology
Lowest Today 10.19
Highest Today 10.45
Today’s Open 10.3
Prev. Close 10.26
52 Week High 11.23
52 Week Low 2.60
Day’s Range: Low 10.19 High 10.45
52-Week Range: Low 2.60 High 11.23
1 day return -
1 Week return -6.02
1 month return -0.86
3 month return +3.62
6 month return +60.78
1 year return +113.04
3 year return +63.59
5 year return -74.55
10 year return -

Design Therapeautics, Inc. Institutional Holdings

SR ONE CAPITAL MANAGEMENT, LP 10.81

Logos Global Management LP 6.05

Point72 Asset Management, L.P. 5.53

Baker Bros Advisors LP 3.70

BlackRock Inc 3.38

TANG CAPITAL MANAGEMENT LLC 2.95

Vanguard Group Inc 2.70

Vivo Capital, LLC 2.67

Almitas Capital LLC 2.53

RA Capital Management, LLC 2.42

Driehaus Capital Management LLC 1.95

Vanguard Total Stock Mkt Idx Inv 1.63

Woodline Partners LP 1.56

Kynam Capital Management, LP 1.30

FMR Inc 1.28

Geode Capital Management, LLC 1.13

State Street Corp 1.05

Acadian Asset Management LLC 1.02

Fidelity Select Biotechnology 1.02

iShares Russell 2000 ETF 1.00

MPM Oncology Impact Management LP 0.92

Frazier Life Sciences Management, L.P. 0.86

Citadel Advisors Llc 0.76

Vanguard Institutional Extnd Mkt Idx Tr 0.51

State St Russell Sm/Mid Cp® Indx SL Cl I 0.44

Fidelity Small Cap Index 0.39

iShares Biotechnology ETF 0.39

iShares Russell 2000 Value ETF 0.34

Fidelity Extended Market Index 0.26

Schwab US Small-Cap ETF™ 0.24

Invesco Dorsey Wright SmallCap Momt ETF 0.24

Fidelity Enhanced Small Cap ETF 0.22

Vanguard Russell 2000 ETF 0.19

North Square Dynamic Small Cap I 0.19

IMC US Ultra Micro Cap 0.16

Nuveen Equity Index R6 0.15

DFA US Small Cap I 0.14

State St Russell Sm Cap® Indx SL Cl I 0.12

Blackrock Extended Mkt Fund CF 0.12

iShares Micro-Cap ETF 0.10

Design Therapeautics, Inc. Market Status

Strong Buy: 0

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Design Therapeautics, Inc. Fundamentals

Market Cap 635.84 M

PB Ratio 2.9892

PE Ratio 0.0

Enterprise Value 416.91 M

Total Assets 226.20 M

Volume 394353

Design Therapeautics, Inc. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:226000 0.2M, FY19:834000 0.8M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-72360000 -72.4M, FY22:-58617000 -58.6M, FY21:-35533000 -35.5M, FY20:-8280000 -8.3M, FY19:-2047000 -2.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-14589000 -14.6M, Q2/2025:-152000 -0.2M, Q1/2025:-159000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-151000 -0.2M

Quarterly Net worth Q3/2025:-16997000 -17.0M, Q2/2025:-19083000 -19.1M, Q1/2025:-17715000 -17.7M, Q3/2024:-13039000 -13.0M, Q2/2024:-11793000 -11.8M

About Design Therapeautics, Inc. & investment objective

Company Information Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Organisation Biotechnology

Employees 54

Industry Biotechnology

CEO Mr. Pratik Shah Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Design Therapeautics, Inc. FAQs

What is the share price of Design Therapeautics, Inc. today?

The current share price of Design Therapeautics, Inc. is $10.31.

Can I buy Design Therapeautics, Inc. shares in India?

Yes, Indian investors can buy Design Therapeautics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Design Therapeautics, Inc. shares in India?

You can easily invest in Design Therapeautics, Inc. shares from India by:

Can I buy fractional shares of Design Therapeautics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Design Therapeautics, Inc.?

Design Therapeautics, Inc. has a market cap of $635.84 M.

In which sector does Design Therapeautics, Inc. belong?

Design Therapeautics, Inc. operates in the Biotechnology sector.

What documents are required to invest in Design Therapeautics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Design Therapeautics, Inc.?

The PE ratio of Design Therapeautics, Inc. is N/A and the PB ratio is 2.99.